AMP-303
An intradermal injection that produced a measurable hair-count increase in its first human trial — and is not the SCUBE3 programme it gets confused with.
- Developed by
- Amplifica
- Current phase
- Phase 1
- Indications
- Androgenetic alopecia
- Also known as
- AMP303
- Last public activity
- Never
- Record confidence
- Medium
First tests in humans. Answers 'is it safe?', not 'does it work?'.
How it is meant to work
Amplifica has not published AMP-303's mechanism. It is worth separating from SCUBE3, the molecule the company is best known for and a different candidate in its pipeline — the two are routinely conflated in coverage of this programme.
Why it matters
The first-in-human trial used a split-scalp design, injecting one side and placebo the other, which controls for the thing hair-loss trials control worst. The sponsor reports a statistically significant proportion of subjects with a greater than 15% increase in non-vellus hair count over placebo at 60 days, still above 10% at 150 days, from a single injection cycle. Read it as an early safety-and-signal study rather than an efficacy result: small, sponsor-reported, and not peer-reviewed.
Development history
No phase changes recorded yet.
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
No trials matched to this programme in ClinicalTrials.gov.
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Amplifica's AMP-303 Study Unveils New Hope for Hair Loss Treatments — Company release